Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of HMPL-689 in Healthy Volunteers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02631642
Recruitment Status : Completed
First Posted : December 16, 2015
Last Update Posted : August 17, 2017
Sponsor:
Information provided by (Responsible Party):
Hutchison Medipharma Limited

Brief Summary:
The purpose of this study is to evaluate the safety and tolerability of a single dose of HMPL-689 in healthy volunteers To determine the pharmacokinetic profile of single oral doses of HMPL-689 in healthy volunteers

Condition or disease Intervention/treatment Phase
Healthy Volunteers Drug: HMPL-689 Drug: HMPL-689 placebo Phase 1

Detailed Description:

Subjects will receive a single dose of HMPL-689 or matching placebo during Day 1. The planned dose levels are: 1, 2.5, 5, 10, 20, 25 and 30 mg (about 7 cohorts of 8 subjects). In each dose cohort, 8 subjects will be randomized to receive HMPL-689 (6 subjects) or placebo (2 subjects) under fed condition with a standard meal.

For the first dose Cohort (1 mg), a sentinel group of 2 subjects (1 HMPL-689 and 1 placebo) will be dosed 24 hours prior to the planned dosing of the remaining six subjects. The decision of dose escalation or study termination will be made jointly by the principal investigator and the sponsor based on the clinical data (safety, tolerability, available PK data and clinical laboratory values). Any dose level may be repeated, reduced or split into 2 doses if deemed appropriate by the Principal Investigator and Sponsor's medical Expert.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 48 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Health Services Research
Official Title: A Phase I,Randomized,Double Blinded,Placebo-controlled,Dose-escalating Study of the Safety,Tolerability and Pharmacokinetics of HMPL-689 in Healthy Volunteers
Actual Study Start Date : March 23, 2016
Actual Primary Completion Date : October 26, 2016
Actual Study Completion Date : February 28, 2017

Arm Intervention/treatment
Experimental: HMPL-689
Subjects will receive a single dose of HMPL-689 or matching placebo on Day 1. The planned dose levels in ascending order are: 1, 2.5, 5, 10, 20, 25 and 30 mg (7 dose cohorts with 8 subjects in each cohort). Within each cohort, randomization ratio of 3:1 is followed to dose 6 subjects with HMPL-689 and 2 subjects with placebo.
Drug: HMPL-689
selective PI3Kδ inhibitor
Other Name: Huchison Medipharma

Placebo Comparator: HMPL-689 placebo
Subjects will receive a single dose of HMPL-689 or matching placebo on Day 1. The planned dose levels in ascending order are: 1, 2.5, 5, 10, 20, 25 and 30 mg (7 dose cohorts with 8 subjects in each cohort). Within each cohort, randomization ratio of 3:1 is followed to dose 6 subjects with HMPL-689 and 2 subjects with placebo.
Drug: HMPL-689 placebo
placebo of HMPL-689
Other Name: Huchison Medipharma




Primary Outcome Measures :
  1. dose limited toxicities evaluated with NCI CTCAE v4.03 [ Time Frame: within 28 days after the first dose ]
    Incidence of dose limited toxicities and associated dose of HMPL-689


Secondary Outcome Measures :
  1. maximum plasma concentration calculated with Blood samples [ Time Frame: within 29 days after the first dose ]
    Blood samples will be taken to measure the levels of study drug

  2. time to reach maximum concentration calculated with Blood samples [ Time Frame: within 29 days after the first dose ]
    Blood samples will be taken to measure the levels of study drug



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Informed consent must be obtained in writing for all subjects before enrollment into the study
  2. Healthy male subjects aged 18 to 45 years inclusive at the time of screening
  3. Body mass index ≥19.0 and ≤ 30.0 kg/m2
  4. Willing to comply with the contraceptive requirements of the study and must not donate sperm during the study or for 3 months afterwards. Subjects must agree to use a condom or to abstain from sexual intercourse throughout the trial and for 30 days afterwards

Exclusion Criteria:

  1. Family history of premature Coronary Heart Disease
  2. History of immunosuppression or opportunistic infections or receipt of a live virus vaccination within the 3 months prior to screening
  3. Clinically significant abnormalities as determined by medical history physical examination, or laboratory test, especially for liver and renal function
  4. Clinically significant findings in ECG, blood pressure and heart rate, as determined by the Clinical Investigator
  5. Subjects at risk for tuberculosis (TB), which is defined as:

    1. Current clinical or laboratory evidence of active TB
    2. History of TB
    3. A positive QuantiFERON® test at screening or within 6 months prior to Day 1
  6. Any medical condition requiring regular use of medication
  7. Exposure to prescription medications within 30 days prior to Day 1
  8. Exposure to any other medication, including over-the-counter medications, herbal remedies and vitamins 14 days prior to first dose (except for paracetamol)
  9. Participation in another clinical trial with any investigational drug within 30 days of Day 1
  10. Treatment in the previous 3 months with any drug known to have a well-defined potential for toxicity to a major organ
  11. Current smoker of more than 10 cigarettes or equivalent/ day prior to commencing the study and unable to completely stop smoking during the study
  12. Symptoms of a clinically significant illness in the 3 months before the study
  13. Presence or sequelae of gastrointestinal, liver or kidney disease, or other conditions known to interfere with the absorption, distribution, metabolism, or excretion of drugs
  14. Chronic constipation or diarrhea, irritable bowel syndrome, inflammatory bowel disease, hemorrhoids or anal diseases with regular or recent presence of blood in feces
  15. History of significant allergic disease (e.g. allergic to medications) and acute phase of allergic rhinitis in the previous 2 weeks before randomization/ enrollment or any food allergy
  16. Clinically significant history of liver disease, including cirrhosis, current alcohol abuse, or current known active infection with HIV, hepatitis B virus (HBV), or hepatitis C virus (HCV)
  17. Current evidence of drug abuse or history of drug abuse within one year before randomization/ enrollment
  18. Mental condition rendering the subject incapable to understand the nature, scope, and possible consequences of the study
  19. Unlikely to comply with the clinical study protocol; e.g. uncooperative attitude, inability to return for follow-up visits, and improbability of completing the study
  20. Subject is the investigator or any sub-investigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the protocol

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02631642


Locations
Layout table for location information
Australia, Victoria
Nucleus Network
Melbourne, Victoria, Australia, 3001
Sponsors and Collaborators
Hutchison Medipharma Limited
Investigators
Layout table for investigator information
Principal Investigator: Jason Lickliter Nucleus Network Ltd

Layout table for additonal information
Responsible Party: Hutchison Medipharma Limited
ClinicalTrials.gov Identifier: NCT02631642     History of Changes
Other Study ID Numbers: 2015-689-00AU2
First Posted: December 16, 2015    Key Record Dates
Last Update Posted: August 17, 2017
Last Verified: August 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No